0.00Open0.04Pre Close0 Volume100 Open Interest3.00Strike Price0.00Turnover0.00%IV310.04%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.04Time Value100Contract SizeAmericanOptions Type--Delta--Gamma18.54Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Biora Therapeutics Stock Discussion
NEWS
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Benzinga· 2 mins ago
Dow Jones· 1 min ago
Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood
Remainder of BT-600 clinical trial progressing well and on schedule
No comment yet